ESR1 and breast carcinoma: In conclusion, our pre-clinical results support the combination of amcenestrant and HER2-targeted agents as a therapeutic strategy in HER2+/ER+ breast cancer, particularly if accompanied by further investigation of appropriate biomarkers of response to amcenestrant associated with ER expression and/or dependency.